Literature DB >> 19885576

Medical management of brain metastases from lung cancer (Review).

Ryuya Yamanaka1.   

Abstract

Brain metastases are a frequent complication in patients with lung cancer and a significant cause of morbidity and mortality. The prognosis of these patients is poor. Medical therapies for brain metastases are neither well-studied nor established. This review analyzes the impact of medical treatment on survival by reviewing recent articles of the management of brain metastases from lung cancer patients. Chemotherapy for brain metastases from lung cancer is effective for both small cell and non-small cell lung cancer. Since brain metastases are part of systemic progression, chemotherapy should always be considered for the therapeutic management of brain metastases. Available data and response rates in lung cancer patients indicated that medical treatment for the management of brain metastases should be part of a multimodality treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19885576     DOI: 10.3892/or_00000564

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  24 in total

Review 1.  Chemoprevention for brain metastases.

Authors:  Van A Trinh; Wen-Jen Hwu
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Authors:  Anna Sophie Berghoff; Astrid Kerstin Kovanda; Thomas Melchardt; Rupert Bartsch; Johannes A Hainfellner; Bence Sipos; Jens Schittenhelm; Christoph C Zielinski; Georg Widhalm; Karin Dieckmann; Michael Weller; Simon L Goodman; Peter Birner; Matthias Preusser
Journal:  Clin Exp Metastasis       Date:  2014-08-24       Impact factor: 5.150

Review 3.  Molecular determinants of lung cancer metastasis to the central nervous system.

Authors:  Timothy G Whitsett; Landon J Inge; Harshil D Dhruv; Philip Y Cheung; Glen J Weiss; Ross M Bremner; Jeffrey A Winkles; Nhan L Tran
Journal:  Transl Lung Cancer Res       Date:  2013-08

Review 4.  Surgical management of advanced non-small cell lung cancer.

Authors:  Gonzalo Varela; Pascal Alexandre Thomas
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 5.  Brain metastases as preventive and therapeutic targets.

Authors:  Patricia S Steeg; Kevin A Camphausen; Quentin R Smith
Journal:  Nat Rev Cancer       Date:  2011-04-07       Impact factor: 60.716

6.  Apoptosis of human non-small-cell lung cancer A549 cells triggered by evodiamine through MTDH-dependent signaling pathway.

Authors:  Yanmei Zou; Xiaomin Qin; Hua Xiong; Feng Zhu; Tao Chen; Hongge Wu
Journal:  Tumour Biol       Date:  2015-02-05

7.  Significance of Trask protein interactions in brain metastatic cohorts of lung cancers.

Authors:  Hua Wu; Li-Qun Shang; Rui-Lin Chen; Shu-Mei Yang; Shui-Li Wang; Jun Wang; Gang Sun
Journal:  Tumour Biol       Date:  2015-01-21

8.  Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases.

Authors:  A S Berghoff; A Ilhan-Mutlu; A Wöhrer; M Hackl; G Widhalm; J A Hainfellner; K Dieckmann; T Melchardt; B Dome; H Heinzl; P Birner; M Preusser
Journal:  Strahlenther Onkol       Date:  2014-02-28       Impact factor: 3.621

9.  Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.

Authors:  Maria Sambade; Allison Deal; Allison Schorzman; J Christopher Luft; Charles Bowerman; Kevin Chu; Olga Karginova; Amanda Van Swearingen; William Zamboni; Joseph DeSimone; Carey K Anders
Journal:  Nanomedicine (Lond)       Date:  2016-07-26       Impact factor: 5.307

10.  Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.

Authors:  Priya Kumthekar; Sean A Grimm; Michael J Avram; Virginia Kaklamani; Irene Helenowski; Alfred Rademaker; Mary Cianfrocca; William Gradishar; Jyoti Patel; Mary Mulcahy; Katie McCarthy; Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2013-01-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.